lurtotecan liposome

Lurtotecan liposome is a liposomal formulation of the topoisomerase I inhibitor lurtotecan. Lurtotecan is a synthetic camptothecin analog, structurally related to irinotecan and topotecan, designed to inhibit DNA replication in cancer cells by stabilizing the cleavable complex between topoisomerase I and DNA, leading to double-strand DNA breaks and cell death. The encapsulation of lurtotecan in a liposomal carrier aims to improve its pharmacokinetic profile, enhance tumor targeting via the enhanced permeability and retention (EPR) effect, reduce systemic toxicity compared to non-liposomal formulations, and potentially overcome drug resistance mechanisms. Lurtotecan liposome has been investigated primarily for oncological indications such as ovarian cancer and other solid tumors.

Other names

liposomal lurtotecanlurtotecan liposomelurtotecan liposomallow-clearance unilamellar liposomal lurtotecanliposomal formulation of lurtotecanliposomal GI147211